{"nctId":"NCT00354835","briefTitle":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","startDateStruct":{"date":"2006-12-26","type":"ACTUAL"},"conditions":["Adult Rhabdomyosarcoma","Childhood Alveolar Rhabdomyosarcoma","Childhood Botryoid-Type Embryonal Rhabdomyosarcoma","Childhood Embryonal Rhabdomyosarcoma","Localized Childhood Soft Tissue Sarcoma","Rhabdomyosarcoma","Sarcoma","Stage I Adult Soft Tissue Sarcoma AJCC v7","Stage II Adult Soft Tissue Sarcoma AJCC v7","Stage III Adult Soft Tissue Sarcoma AJCC v7"],"count":481,"armGroups":[{"label":"Arm I (chemotherapy, radiotherapy)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Biological: Dactinomycin","Other: Laboratory Biomarker Analysis","Other: Questionnaire Administration","Radiation: Radiation Therapy","Drug: Vincristine Sulfate"]},{"label":"Arm II (chemotherapy, radiotherapy)","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclophosphamide","Biological: Dactinomycin","Drug: Irinotecan Hydrochloride","Other: Laboratory Biomarker Analysis","Other: Questionnaire Administration","Radiation: Radiation Therapy","Drug: Vincristine Sulfate"]}],"interventions":[{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Dactinomycin","otherNames":["Actinomycin A IV","Actinomycin C1","Actinomycin D","Actinomycin I1","Actinomycin IV","Actinomycin X 1","Actinomycin-[thr-val-pro-sar-meval]","Cosmegen","DACT","Dactinomycine","Lyovac Cosmegen","Meractinomycin"]},{"name":"Irinotecan Hydrochloride","otherNames":["Campto","Camptosar","Camptothecin 11","Camptothecin-11","CPT 11","CPT-11","Irinomedac","Irinotecan Hydrochloride Trihydrate","Irinotecan Monohydrochloride Trihydrate","U-101440E"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Questionnaire Administration","otherNames":[]},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]},{"name":"Vincristine Sulfate","otherNames":["Kyocristine","Leurocristine Sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with newly diagnosed embryonal RMS, botryoid or spindle cell variants of embryonal RMS, ectomesenchymoma, or alveolar RMS are eligible for this study\n* Enrollment on COG-D9902 to confirm local histologic diagnosis with central pathology review is required for all patients\n* Patients may be enrolled on ARST0531 and start protocol treatment prior to receipt of central pathology review results\n* Patient must have Intermediate-risk RMS defined as:\n\n  * Embryonal, botryoid, or spindle cell RMS, or ectomesenchymoma: stage 2 or 3 and group III OR\n  * Alveolar RMS: stage 1-3 and group I-III\n* Staging ipsilateral retroperitoneal lymph node dissection (SIRLND) is required for all patients \\>= 10 years of age with paratesticular tumors and for patients \\< 10 years with clinically or radiographically involved lymph nodes (except when extensive lymph node involvement, defined as two or more lymph nodes \\> 2 cm in dimension, is identified by imaging studies)\n* Regional lymph node sampling or sentinel lymph node procedure is required for histologic evaluation in patients with extremity tumors\n* Clinically or radiographically enlarged nodes should be sampled for histologic evaluation\n* Detection of metastasis by optional FDG PET (not required for study enrollment); FDG PET may detect abnormalities suggestive of metastasis not identified by bone scan, computed tomography (CT), or bone marrow aspiration/biopsy; the prognostic significance of FDG PET-detected abnormalities is not clear; FDG PET-detected abnormalities MUST be confirmed to be metastases by an additional imaging modality (such as magnetic resonance imaging \\[MRI\\] or CT) OR pathologic confirmation; unless FDG PET abnormalities are confirmed by another imaging modality or biopsy, FDG PET abnormalities will NOT be considered evidence of metastasis\n* Patients must have a performance status of 0, 1, or 2; the Lansky performance score should be used for patients \\< 16 years and the Karnofsky performance score for patients \\>= 16 years\n* Patients who have received prior chemotherapy (excluding steroids) or radiation therapy, except for patients transferring from ARST0331 (low-risk study), are not eligible\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \\>= 70 ml/min/1.73 m\\^2 or a serum creatinine based on age/gender as follows:\n\n  * 1 month to \\< 6 months: 0.4 mg/dL\n  * 6 months to \\< 1 year: 0.5 mg/dL\n  * 1 to \\< 2 years: 0.6 mg/dL\n  * 2 to \\< 6 years: 0.8 mgt/dL\n  * 6 to \\< 10 years: 1 mg/dL\n  * 10 to \\< 13 years: 1.2 mg/dL\n  * 13 to \\< 16 years: 1.5 mg/dL (males) or 1.4 mg/dL (females)\n  * \\>= 16 years: 1.7 mg/dL (males) or 1.4 mg/dL (females)\n* Patients with urinary tract obstruction by tumor must meet the renal function criteria AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract\n* Total bilirubin =\\< 1.5 x upper limit of normal for age\n* Peripheral absolute neutrophil count (ANC) \\>= 750/uL\n* Platelet count \\>= 75,000/uL (transfusion independent)\n* No evidence of uncontrolled infection\n* Patients must be able to undergo radiation therapy, if necessary, as specified in the protocol\n* Female patients of childbearing potential must have a negative pregnancy test\n* Female patients who are breast feeding must agree to stop breast feeding\n* Sexually active patients of childbearing potential must be willing to use effective contraception during therapy and for at least 1 month after treatment is completed\n* All patients and/or their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met","healthyVolunteers":false,"sex":"ALL","maximumAge":"49 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event Free Survival (EFS)","description":"Probability of no relapse, secondary malignancy, or death after 4 year in the study","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6255","spread":null},{"groupId":"OG001","value":"0.5874","spread":null}]}]}]},{"type":"PRIMARY","title":"Response Rate (RR)","description":"Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at \\> 4 weeks; Partial Response (PR): At least 64% decrease in volume compared to the baseline; Overall Response (OR) = CR + PR.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6667","spread":null},{"groupId":"OG001","value":"0.6726","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Probability of being alive after 4 years in the study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7293","spread":null},{"groupId":"OG001","value":"0.7223","spread":null}]}]}]},{"type":"SECONDARY","title":"Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison","description":"Compare 4-year EFS using eligible participants only to the historical rate of 0.65 with IRSI-V. The 4-year EFS is probability of no relapse, secondary malignancy, or death after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.65.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6255","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Failure","description":"Compare 2-year local failure rate to the historical rate of 0.13 with IRSI-V. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.13.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1757","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison","description":"Compare 4-year OS using eligible participants only to the historical rate of 0.70 with IRSI-V. The 4-year OS is probability of being alive after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.70.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7293","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Toxicity","description":"Grade 3 or 4 nausea, diarrhea, dehydration, radiation dermatitis, mucositis due to radiation. Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2072","spread":null},{"groupId":"OG001","value":"0.3673","spread":null}]}]}]},{"type":"SECONDARY","title":"Acute and Late Effects of VAC as Delivered on This Study to D9803 VAC","description":"The toxicity rates will be estimated for each phase and course of treatment, and will be compared to the fixed rates under D9803 using one-sided lower confidence intervals for a single proportion without adjustment for multiple comparisons.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 4","description":"4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2857","spread":null},{"groupId":"OG001","value":"0.6364","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15","description":"4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6667","spread":null},{"groupId":"OG001","value":"0.5686","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Toxicity Related to VI Treatment in Patients With UGT1A1 Genotype","description":"Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity With CYP2B6 Genotypes","description":"Incidence of toxicity related to VAC treatment in patients with CYP2B6 genotypes.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Toxicity With GSTA1 and CYP2C9 Genotypes","description":"Incidence of toxicity related to VAC treatment in patients with GSTA1 and CYP2C9 genotypes.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Event Free Survival (EFS) by PAX Status","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null},{"groupId":"OG001","value":"0.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Bladder Dysfunction","description":"Number of patients with a summary score greater than 8.5","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":222},"commonTop":["Neutrophil count decreased","White blood cell decreased","Anemia","Platelet count decreased","Febrile neutropenia"]}}}